These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 8811495)

  • 1. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.
    Murray JL; Kleinerman ES; Jia SF; Rosenblum MG; Eton O; Buzaid A; Legha S; Ross MI; Thompson L; Mujoo K; Rieger PT; Saleh M; Khazaeli MB; Vadhan-Raj S
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):206-17. PubMed ID: 8811495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
    Choi BS; Sondel PM; Hank JA; Schalch H; Gan J; King DM; Kendra K; Mahvi D; Lee LY; Kim K; Albertini MR
    Cancer Immunol Immunother; 2006 Jul; 55(7):761-74. PubMed ID: 16187086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating.
    Chen RL; Reynolds CP; Seeger RC
    Cancer Immunol Immunother; 2000 Feb; 48(11):603-12. PubMed ID: 10663607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.
    Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
    Cancer Immunol Immunother; 1999 Nov; 48(8):463-70. PubMed ID: 10550551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients.
    Uttenreuther-Fischer MM; Huang CS; Yu AL
    Cancer Immunol Immunother; 1995 Dec; 41(6):331-8. PubMed ID: 8635190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma.
    Spitler LE; Cao H; Piironen T; Whiteside TL; Weber RW; Cruickshank S
    Am J Clin Oncol; 2017 Apr; 40(2):207-213. PubMed ID: 25286079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma.
    Kremens B; Hero B; Esser J; Weinel P; Filger-Brillinger J; Fleischhack G; Graf N; Grüttner HP; Niemeyer C; Schulz A; Wickmann L; Berthold F
    Cancer Immunol Immunother; 2002 Apr; 51(2):107-10. PubMed ID: 11904735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice.
    Kendra K; Gan J; Ricci M; Surfus J; Shaker A; Super M; Frost JD; Rakhmilevich A; Hank JA; Gillies SD; Sondel PM
    Cancer Immunol Immunother; 1999 Aug; 48(5):219-29. PubMed ID: 10478638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia.
    Patnaik MM; Sallman DA; Mangaonkar AA; Heuer R; Hirvela J; Zblewski D; Al-Kali A; Binder M; Balasis ME; Newman H; Letson C; Kruer TL; Gangat N; Komrokji RS; Tefferi A; Lo A; Shih T; Durrant C; List AF; Padron E
    Blood; 2020 Aug; 136(7):909-913. PubMed ID: 32294158
    [No Abstract]   [Full Text] [Related]  

  • 10. Analytical characterization of ch14.18: a mouse-human chimeric disialoganglioside-specific therapeutic antibody.
    Soman G; Kallarakal AT; Michiel D; Yang X; Saptharish N; Jiang H; Giardina S; Gilly J; Mitra G
    MAbs; 2012; 4(1):84-100. PubMed ID: 22327432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous Four-Week Repeated Dose Toxicity Studies of Rice Cell-Derived Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Rats.
    Ji JE; Lee JM; Choi JM; Choi YH; Kim EK; Chu SJ; Kim SK; Ahn KH; Lee DH; Kim HH; Han K; Kim DK
    Toxicol Res; 2008 Dec; 24(4):315-320. PubMed ID: 32038810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effects of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Gel on Third-Degree Frostbite Wounds in Northeastern China: A Randomized Controlled Trial.
    Zhang XH; Cui CL; Zhu HY; Wang J; Xue Y; Zhang N; Sun ZA; Gao XX; Zhou X; Yu JA; Chen XX
    J Burn Care Res; 2023 May; 44(3):715-722. PubMed ID: 32006002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma.
    Irie RF; Ollila DW; O'Day S; Morton DL
    Cancer Immunol Immunother; 2004 Feb; 53(2):110-7. PubMed ID: 14564483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer.
    Goodman GE; Hellstrom I; Yelton DE; Murray JL; O'Hara S; Meaker E; Zeigler L; Palazollo P; Nicaise C; Usakewicz J
    Cancer Immunol Immunother; 1993; 36(4):267-73. PubMed ID: 8382560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GD2-targeting therapy: a comparative analysis of approaches and promising directions.
    Philippova J; Shevchenko J; Sennikov S
    Front Immunol; 2024; 15():1371345. PubMed ID: 38558810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting.
    Sabbih GO; Danquah MK
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal Antibody Therapies for High Risk Neuroblastoma.
    Furman WL
    Biologics; 2021; 15():205-219. PubMed ID: 34135571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.
    Vacchelli E; Pol J; Bloy N; Eggermont A; Cremer I; Fridman WH; Galon J; Marabelle A; Kohrt H; Zitvogel L; Kroemer G; Galluzzi L
    Oncoimmunology; 2015 Jan; 4(1):e985940. PubMed ID: 25949870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dinutuximab: first global approval.
    Dhillon S
    Drugs; 2015 May; 75(8):923-7. PubMed ID: 25940913
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.